Buphenyl Therapy for Byler's Disease

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a single patient compassionate use protocol to determine whether Buphenyl (4-phenylbutyrate) will improve the poor bile flow associated with Byler Disease.

Details

• Lead Sponsor: University of Pittsburgh
• Treatments: 4-phenylbutyric acid

Criteria

Inclusion Criteria:

• Byler Disease

• Cholestasis unresponsive to pharmacologic therapy

Exclusion Criteria:

• Allergy/Hypersensitivity to Buphenyl